Sales & Marketing News | pharmaphorum

News

More than a year after it was rejected by the FDA, Satsuma Pharma's intranasal migraine therapy Atzumi has been given the go-ahead by the agency.

News

Shares in Eli Lilly have weakened after pharmacy benefit manager CVS Health said it would no longer cover its weight-loss therapy Zepbound.

News

Johnson & Johnson has its first regulatory approval for FcRn blocker Imaavy, getting a green light in the US for generalised myasthenia gravis (gMG).

News

GSK has said it is not too worried about the impact of potential pharma-specific US tariff rules as it posts a solid set of first-quarter results.

News

AstraZeneca has said it is considering a shift in the production of some medicines from Europe to the US in order to sidestep potential tariffs.

News

Abeona Therapeutics' Zevaskyn has been approved in the US as a treatment for the rare skin disorder recessive dystrophic epidermolysis bullosa (DEB).